BioSpace News Archive

BioInvent International AB, a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, announces updated positive interim top-line data from its novel anti-FcyRIIB antibody BI-1206 that show increased response levels and sustained complete responses.

Forma Therapeutics Holdings, Inc. announced etavopivat, the company’s investigational oral, once-daily, selective pyruvate kinase-R activator, significantly improved anemia and red blood cell health with a favorable tolerability and safety profile in patients with SCD.

BeiGene, a global, science-driven biotechnology company focused on developing innovative and affordable medicines, presented additional safety and efficacy results from an ongoing Phase 2 trial evaluating BRUKINSA® in patients with previously treated B-cell malignancies who were intolerant to ibrutinib and/or acalabrutinib.

Cellectis announced preliminary results from the BALLI-01 Phase 1 study of UCART22, its allogeneic CAR-T cell therapy candidate targeting CD22, in patients with relapsed or refractory B-cell acute lymphoblastic leukemia, and preclinical data on TALGlobin01, its autologous cell therapy product candidate for homozygous SCD patients at the 63rd Annual Meeting of the American Society of Hematology in Atlanta, Georgia.

MorphoSys US Inc., a fully owned subsidiary of MorphoSys AG, and Incyte announced additional real-world evidence results from the RE-MIND2 study comparing tafasitamab in combination with lenalidomide against the most frequently used treatments in adult patients with relapsed or refractory diffuse large B-cell lymphoma.

IGM Biosciences, Inc., a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, announced the presentation of clinical results from the Company’s Phase 1 trial evaluating IGM-2323, a novel bispecific IgM antibody targeting CD20 x CD3, at the 63rd American Society of Hematology Annual Meeting and Exposition.

Daiichi Sankyo Company, Limited announced that valemetostat, a potential first-in-class dual inhibitor of EZH1 and EZH2, demonstrated promising response rates in a pivotal phase 2 study in Japanese patients with relapsed/refractory adult T-cell leukemia/lymphoma.

Kite, a Gilead Company, announced updated two-year results from ZUMA-5, a global, multicenter, single-arm, open-label Phase 2 study evaluating Yescarta® in adult patients with relapsed or refractory indolent non-Hodgkin lymphoma after at least two prior lines of therapy.

Regeneron Pharmaceuticals, Inc. announced new results for higher dose level cohorts of its investigational REGN5458 bispecific antibody, which were presented in an oral session at the 2021 American Society of Hematology Annual Meeting in Atlanta, GA.

As the COVID-19 pandemic continues to evolve, five studies being presented during the 63rd American Society of Hematology Annual Meeting and Exposition shed light on the persisting burden that COVID-19 has had on people with underlying blood disorders.